Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn's disease: Results from the phase 3 VIVID 1 study

被引：0
|
作者：
Jairath, V. [1 ,2 ]
Sands, B. E. [3 ]
Bossuyt, P. [4 ]
Farraye, F. [5 ]
Ferrante, M. [6 ]
Hisamatsu, T. [7 ]
Kaser, A. [8 ]
Kierkus, J. [9 ]
Laharie, D. [10 ]
Reinisch, W. [11 ]
Siegmund, B. [12 ]
Bragg, S. M. [13 ]
Hon, E. [13 ]
Lin, Z. [13 ]
Lopes, M. Ugolini [13 ]
Morris, N. [13 ]
Protic, M. [13 ]
Danese, S. [14 ,15 ]
机构：
[1] Univ Hosp, Div Gastroenterol, Dept Med, London, ON, Canada
[2] Western Univ, Div Epidemiol & Biostat, London, ON, Canada
[3] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
[4] Imelda Gen Hosp, Dept Gastroenterol, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[5] Mayo Clin Florida, Div Gastroenterol & Hepatol, Jacksonville, FL USA
[6] Katholieke Univ Leuven, Leuven Univ Hosp, Dept Gastroenterol & Hepatol, Leuven, Belgium
[7] Kyorin Univ, Dept Gastroenterol & Hepatol, Sch Med, Tokyo, Japan
[8] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Jeffrey Cheah Biomed Ctr, Cambridge, England
[9] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pe, Warsaw, Poland
[10] Univ Bordeaux, CHU Bordeaux, Hop Haut Leveque, Serv Hepatogastroenterol & Oncol Digest, Bordeaux, France
[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria
[12] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany
[13] Eli Lilly & Co, Immunol, Indianapolis, IN USA
[14] Univ Vita Salute San Raffaele, Gastroenterol & Gastrointestinal Endoscopy Unit, Milan, Italy
[15] Osped San Raffaele, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP35
引用
收藏
页码：I62 / I64
页数：3
相关论文
共 50 条
  • [1] Primary efficacy and safety of mirikizumab in moderate to severe Crohn's Disease: results of the treat-through VIVID 1 study
    Ferrante, M.
    Danese, S.
    Chen, M.
    D'Haens, G.
    Ghosh, S.
    Hisamatsu, T.
    Jairath, V.
    Kierkus, J.
    Peyrin-Biroulet, L.
    Siegmund, B.
    Bragg, S. M.
    Crandall, W.
    Gibble, T. Hunter
    Lin, Z.
    Lopes, M. Ugolini
    Morris, N.
    Carlier, H.
    Sands, B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I7 - I9
  • [2] EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE IN BRAZIL
    Prra, Rogerio S.
    Chebli, Julio
    Chebli, Liliana
    Bertges, Erika R.
    Ambrogini Junior, Orlando
    Schiavetti, Bianca
    Alves, Antonio, Jr.
    Flores, Cristina
    Lubini, Marcio
    Gasparetti, Newton, Jr.
    Bafutto, Mauro
    Azevedo, Matheus
    Damiao, Aderson O.
    Queiroz, Natalia S.
    Steinwurz, Flavio
    Carvalho, Nayara S.
    Boratto, Sandra D.
    Vilela, Eduardo G.
    Feres, Omar
    Rocha, Jose Joaquim R.
    GASTROENTEROLOGY, 2021, 160 (06) : S414 - S415
  • [3] Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn's Disease: Results From the Phase 3B SEQUENCE Trial
    Peyrin-Biroulet, Laurent
    Chapman, Casey
    Colombel, Jean-Frederic
    Caprioli, Flavio
    D'Haens, Geert
    Ferrante, Marc
    Schreiber, Stefan
    Atreya, Raja
    Danese, Silvio
    Lindsay, James O.
    Bossuyt, Peter
    Siegmund, Britta
    Irving, Peter
    Panaccione, Remo
    Neimark, Ezequiel
    Wallace, Kori
    Anschutz, Toni
    Kligys, Kristina
    Duan, W. Rachel
    Pivorunas, Valerie
    Huang, Xiu
    Berg, Sofie
    Shu, Lei
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S1 - S1
  • [4] Ustekinumab: A Review in Moderate to Severe Crohn’s Disease
    Yvette N. Lamb
    Sean T. Duggan
    Drugs, 2017, 77 : 1105 - 1114
  • [5] Ustekinumab: A Review in Moderate to Severe Crohn's Disease
    Lamb, Yvette N.
    Duggan, Sean T.
    DRUGS, 2017, 77 (10) : 1105 - 1114
  • [6] Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohn's Disease: Results From Three Phase 3 Clinical Trials
    Sands, Bruce E.
    Han, Chenglong
    Naessens, Dominik
    Gasink, Christopher
    Jacobstein, Douglas
    Gao, Long-Long
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S351 - S351
  • [7] Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Kierkus, Jaroslaw
    Higgins, Peter D. R.
    Fischer, Monika
    Jairath, Vipul
    Hirai, Fumihito
    D'Haens, Geert
    Belin, Ruth M.
    Miller, Debra
    Gomez-Valderas, Elisa
    Naegeli, April N.
    Tuttle, Jay L.
    Pollack, Paul F.
    Sandborn, William J.
    GASTROENTEROLOGY, 2022, 162 (02) : 495 - 508
  • [8] Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn's disease
    Pai, Rish
    De Hertogh, Gert
    Reinisch, Walter
    Harpaz, Noam
    Feagan, Brian
    Agada, Noah
    Pollack, Paul
    Chan, Lai Shan
    Protic, Marijana
    Magro, Fernando
    Dhesi, Endip
    GUT, 2023, 72 (SUPPL_2) : A210 - A210
  • [9] Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohn's Disease Patients: Results from the IM-UNITI Maintenance Study
    Sands, Bruce
    Gasink, Chris
    Jacobstein, Doug
    Gao, Long Long
    Johanns, Jewel
    Szapary, Philippe
    Colombel, Jean-Frederic
    Targan, Stephan
    Ghosh, Subrata
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S303
  • [10] Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies
    Li, K.
    Hayden, K.
    Wadman, E.
    Bhagat, S.
    Emrich, S.
    Jacobstein, D.
    Gasink, C.
    Brodmerkel, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S57 - S58
12345